Dr. Patrick W. Burke, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 108
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MI license 4301106087 -
Internal Medicine Physician
IL license 125053531 · MI license 4301106087 -
Medical Oncology Physician
MI license 4301106087
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 108
- Services billed
- 550
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 158 | 66 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 98 | 25 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 14 |
| Hospital discharge day management, 30 minutes or less | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Venclexta (venetoclax) | 73 |
| Acyclovir Other prescribers in Ann Arbor, MI | 31 |
| Voriconazole | 18 |
| Levofloxacin Other prescribers in Ann Arbor, MI | 16 |
| Imatinib Mesylate | 15 |
| Methotrexate (methotrexate sodium) Other prescribers in Ann Arbor, MI | 13 |
| Posaconazole | 13 |
| Promacta (eltrombopag olamine) | 13 |
| Ondansetron Hcl Other prescribers in Ann Arbor, MI | 12 |
| Prednisone Other prescribers in Ann Arbor, MI | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $14,853 in research payments for these studies, mostly to the institutions running them.
- Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic …
Novartis Pharmaceuticals Corporation - TAS1440-01
Taiho Oncology, Inc. - IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
AbbVie Inc. · Active, not recruiting · NCT04086264
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.